CorporateCipla Pharma License Cancellation: FDA Withdraws Order After HC Raps It For Going 'Overboard'BY PTI
NewsFDA Cancels Drug Sale Licence Of Cipla Pharma & Life Sciences's Pune Carry And Forwarding UnitBY PTI
CorporateCipla Pune Unit Loses Drug Sale Licences: What Triggered FDA Action?BY Outlook Business Desk
CorporateUS Pharma Firm Eli Lilly Partners with Cipla to Sell Weight-loss Drug in India under Brand Name ‘Yurpeak’BY Outlook Business Desk
MarketsCipla, Lupin, Aurobindo Shares Drop as Trump’s Push to Boost US Drug Mfg Sours SentimentBY Outlook Business Desk
CorporateCipla Q2 Net Profit Rises 17 Per cent to Rs 1,303 Crore; Income from Operations at Rs 7,051 CroreBY PTI
NewsJasdeep Singh Gill Nominated as Head of Radha Soami Satsang Beas: Know His Journey from Pharma Expert to Dera LeaderBY Outlook Business Desk
MarketsStocks To Watch: Cipla, Bharti Airtel, Colgate-Palmolive And Others In NewsBY Outlook Business Desk
MarketsStocks To Watch: Aster DM, Piramal Enterprises, CDSL, And Others In NewsBY Outlook Business Desk
CorporateCipla Partners With CSIR-CDRI To Develop Formulation For Fungal KeratitisBY Press Trust of India
MarketsStocks To Watch On 23 January: ICICI Bank, Cipla, Zee Entertainment, Others In NewsBY Outlook Business Desk
CorporateCipla To Collaborate With Kemwell Biopharma, Manipal Med Group To Form JV In USBY Press Trust of India
NewsCipla Profit Rises 45% To Rs 1,156 Crore, Sales Up 14.4% To Rs 6,590 Crore In Q2BY Press Trust of India
NewsCipla Profit Rises 45% To Rs 1,156 Crore, Sales Up 14.4% To Rs 6,590 Crore In Q2BY Press Trust of India
CorporateCipla Promoter Sale Hangs In The Balance Due To Discord Over ValuationBY Outlook Business Desk
MarketsStocks To Watch On 3 October: Maruti Suzuki, Cipla, Hindustan Zinc, Others Are TrendingBY Outlook Business Desk
CorporateTorrent Plans To Raise Up To $1 Billion For Cipla Bid, In Talks With Apollo: ReportBY Outlook Business Desk
